Lifecore Biomedical, Inc. (LFCR) Stock Price & Analysis
Lifecore Biomedical, Inc. (LFCR) closed at USD 6.44 on Thursday, October 15, 2026, up 0.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.42; the Oct 15, 2026 session ranged USD 6.43–6.48 on volume of 233,437 shares. Market capitalization is $244.11M, with a 52-week range of USD 3.63–8.98 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LFCR.md
Key facts (LFCR)
- Analysts: Hold (mean 3.00 on a 1–5 scale) (4 analysts), mean target USD 6.28 (range 6.28–6.28).
- Total return with dividends: 1Y -1.4% vs S&P 500 +18.1%; 5Y -34.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.31, revenue estimate $25.5M.
Analysts (LFCR)
Consensus Hold (mean 3.00 on a 1–5 scale), 4 analysts; mean target USD 6.28 (low 6.28, high 6.28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Barrington Research | Downgrade | Outperform → Market Perform | |
| 2026-09-28 | William Blair | Downgrade | Outperform → Market Perform |
Total return (dividends reinvested) (LFCR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -1.4% | -34.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -1.4% | -8.1% |
| Volatility (annualized) | 77.1% | 84.9% |
| Max drawdown | -58.5% (Jan 2026→Mar 2026) | -85.9% (Feb 2022→Mar 2023) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 6.44 |
|---|---|
| Change | ▲ 0.31% (up) |
| Previous Close | USD 6.42 |
| Open | USD 6.44 |
| Day Range | USD 6.43 – 6.48 |
| 52-Week Range | USD 3.63 – 8.98 |
| Volume | 233,437 shares |
| Market Cap | $244.11M |
| Exchange | NMS |
Technical Analysis (LFCR)
Nexqual's technical model rates LFCR "STRONG BUY" based on 6 bullish and 1 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 72.26 (overbought) |
| vs SMA50 | Above (USD 5.04) |
| MACD | 0.49 (positive) |
Analyst Ratings (LFCR)
Wall Street analysts rate LFCR "Hold" based on 4 analysts, with a mean price target of USD 6.28 (range USD 6.28–6.28), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6.28 |
| High Target | USD 6.28 |
| Low Target | USD 6.28 |
| Buy / Hold / Sell | 0 / 4 / 0 |
Earnings (LFCR)
| Next Earnings Date | 2026-11-03 |
|---|---|
| Revenue Estimate | $25.51M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.19 vs est -0.22 ▲ beat |
| 2026-03-31 | USD -0.43 vs est -0.29 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.16 ▲ beat |
| 2025-02-28 | USD -0.47 vs est -0.15 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (LFCR)
| Total Revenue | $129.46M |
|---|---|
| Gross Margin | +31.37% |
| Operating Margin | +7.51% |
| Profit Margin | -23.78% |
| Debt / Equity | 9.72 |
| Current Ratio | 3.49 |
| Total Cash | $17.24M |
| Total Debt | $156.38M |
| Free Cash Flow (fiscal year ended May 2025, SEC 10-K) | -$13.62M (-10.6% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (LFCR)
Nexqual rates Lifecore Biomedical, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -41% YoY (annual), sharp decline |
|---|---|
| Profitability | Solid — Gross margin 31%, operating 8% |
| Balance Sheet | Weak — $17M cash vs $156M debt |
| Cash Flow | Weak — FCF negative: -$14M (FY ended May 2025, 10-K), burning cash |
| Efficiency | Mixed — No data |
Ownership (LFCR)
| Insider Ownership | +3.04% |
|---|---|
| Institutional Ownership | +72.49% |
| Shares Outstanding | 37.91M |
| Float | 19.34M |
| Short % of Float | +8.02% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (LFCR)
Lifecore Biomedical, Inc. is led by Paul Josephs (age 60), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Paul Josephs (age 60) |
|---|---|
| Executive VP & CFO | Ryan D. Lake (age 48) |
| Vice President of Operations | Thomas Guldager |
| Director of Internal Audit & Chief Compliance Officer | Aaron Perlitsh |
| Executive Vice President of Quality & Development Services | Jackie Q. Klecker |
Major Backers & Investors (LFCR)
Notable institutional backers of Lifecore Biomedical, Inc. include WYNNEFIELD CAPITAL INC, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.p., according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| WYNNEFIELD CAPITAL INC | 12.42% |
| Legion Partners Asset Management, LLC | 11.79% |
| Greenhaven Road Investment Management, L.p. | 8.43% |
| 325 Capital Llc | 7.65% |
| Morgan Stanley | 2.03% |
| Fidelity | 1.49% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.1% |
| Vanguard Group | 7.1% |
| Geode Capital | 2.26% |
| State Street | 1.76% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt